NCT06481566View on ClinicalTrials.gov

Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation: a Single-arm, Open-label Clinical Trial

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 21, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

June 30, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
RADIATION

stereotactic ablative body radiotherapy

The residual primary lung lesions after first-line Almonertinib will be delivered stereotactic ablative body radiotherapy.

Trial Locations (1)

400030

RECRUITING

Chongqing University Cancer Hospital, Chongqing

All Listed Sponsors
lead

Chongqing University Cancer Hospital

OTHER